Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3–6 years and 2–35 m...
Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3–6 years and 2–35 months of age- an open-label, randomized phase IIb clinical trial
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights•An inactivated EV-A71 vaccine is safe and immunogenic in children 2 months to 6 years of age. •Adjuvanted 1.0 μg total viral protein elicited higher titers of neutralizing antibody than adjuvanted 0.5 μg total protein. •Elicited neutralizing antibody could last for up to a year.
Alternative Titles
Full title
Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3–6 years and 2–35 months of age- an open-label, randomized phase IIb clinical trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2271846310
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2271846310
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2019.07.096
